Entera Bio (NASDAQ:ENTX – Get Free Report) and Tenax Therapeutics (NASDAQ:TENX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.
Volatility and Risk
Entera Bio has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
Valuation and Earnings
This table compares Entera Bio and Tenax Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entera Bio | $180,000.00 | 687.44 | -$9.54 million | ($0.26) | -10.42 |
| Tenax Therapeutics | N/A | N/A | -$17.60 million | ($1.13) | -6.28 |
Entera Bio has higher revenue and earnings than Tenax Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
14.1% of Entera Bio shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 10.4% of Entera Bio shares are held by company insiders. Comparatively, 3.1% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Entera Bio and Tenax Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entera Bio | -4,525.11% | -77.75% | -68.13% |
| Tenax Therapeutics | N/A | -31.34% | -30.39% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Entera Bio and Tenax Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entera Bio | 1 | 0 | 0 | 1 | 2.50 |
| Tenax Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
Entera Bio presently has a consensus target price of $10.00, indicating a potential upside of 269.00%. Tenax Therapeutics has a consensus target price of $18.00, indicating a potential upside of 153.52%. Given Entera Bio’s higher probable upside, analysts plainly believe Entera Bio is more favorable than Tenax Therapeutics.
Summary
Entera Bio beats Tenax Therapeutics on 8 of the 13 factors compared between the two stocks.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
About Tenax Therapeutics
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
